Home/Pipeline/GEN1046/BNT313 (DuoBody-PD-L1x4-1BB)

GEN1046/BNT313 (DuoBody-PD-L1x4-1BB)

Solid Tumors

Phase 2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 2

Status

Active

Company

Genmab

About Genmab

Founded in 1999, Genmab's mission is to improve the lives of patients through innovative antibody therapeutics. The company has achieved remarkable success with its partnered assets, DARZALEX® and KESIMPTA®, which have become multi-billion dollar therapies, validating its scientific approach. Its strategy combines advancing a deep, wholly-owned clinical pipeline with high-value collaborations, funded by substantial royalty revenue. This hybrid model positions Genmab to sustainably capture value from both its platform innovation and direct drug development.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed